10x Genomics (TXG) Deepens Transplant Research Ties With CareDx, But What Does It Signal Strategically?

Simply Wall St.01-10

On 7 January 2026, CareDx announced a collaboration with 10x Genomics to create ImmuneScape, a multiomics initiative using 10x’s Xenium spatial and Chromium Flex single-cell platforms to study ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602581210?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-01-10 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602581210","market":"sg","top_or_hot":-1,"title":"10x Genomics (TXG) Deepens Transplant Research Ties With CareDx, But What Does It Signal Strategically?","media":"Simply Wall St.","content":"<div>\n<p>On 7 January 2026, CareDx announced a collaboration with 10x Genomics to create ImmuneScape, a multiomics initiative using 10x’s Xenium spatial and Chromium Flex single-cell platforms to study ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-deepens-transplant-research-ties-with-cared\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10x Genomics (TXG) Deepens Transplant Research Ties With CareDx, But What Does It Signal Strategically?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10x Genomics (TXG) Deepens Transplant Research Ties With CareDx, But What Does It Signal Strategically?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 15:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-deepens-transplant-research-ties-with-cared><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On 7 January 2026, CareDx announced a collaboration with 10x Genomics to create ImmuneScape, a multiomics initiative using 10x’s Xenium spatial and Chromium Flex single-cell platforms to study ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-deepens-transplant-research-ties-with-cared\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-deepens-transplant-research-ties-with-cared","article_id":"2602581210","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-deepens-transplant-research-ties-with-cared","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602581210","pubTimestamp":1768029552,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"On 7 January 2026, CareDx announced a collaboration with 10x Genomics to create ImmuneScape, a multiomics initiative using 10x’s Xenium spatial and Chromium Flex single-cell platforms to study transplant organ rejection and therapeutic response.\nThis program aims to generate high-resolution immune maps from FFPE biopsy samples, potentially informing future transplant diagnostics and more personalized treatment selection.\nWe’ll now examine how this ImmuneScape collaboration, centered on 10x’s...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4139":"生物科技","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4121":"生命科学工具和服务","CDNA":"CareDx","TXG":"10x Genomics, Inc."},"translate_title":"10x Genomics(TXG)加深了与CareDx的移植研究联系，但它在战略上发出了什么信号？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1.5,"TXG":1.5},"content_text":"On 7 January 2026, CareDx announced a collaboration with 10x Genomics to create ImmuneScape, a multiomics initiative using 10x’s Xenium spatial and Chromium Flex single-cell platforms to study transplant organ rejection and therapeutic response. This program aims to generate high-resolution immune maps from FFPE biopsy samples, potentially informing future transplant diagnostics and more personalized treatment selection. We’ll now examine how this ImmuneScape collaboration, centered on 10x’s Xenium and Chromium Flex platforms, could influence the company’s broader investment narrative. Find companies with promising cash flow potential yet trading below their fair value.Advertisement10x Genomics Investment Narrative RecapTo own 10x Genomics, you need to believe its single cell and spatial platforms can become essential tools across high value clinical research, while the path to scale is still being built. The ImmuneScape collaboration reinforces demand for Xenium and Chromium Flex in real world, FFPE based studies, but it does not materially change the near term focus on stabilizing consumables growth or the key risk around persistent operating losses in a soft funding backdrop. Among recent updates, the ImmuneScape news sits alongside the ASTRA pan cancer spatial atlas initiative, which also puts Xenium at the center of large scale, multi site research. Together, these collaborations highlight how 10x is embedding its platforms into consortium style projects that could support instrument utilization and reagent pull through over time, while the company still faces pressure from lower average selling prices and product mix shifts. Yet behind these high profile collaborations, investors still need to watch the risk that ongoing operating losses and weaker research budgets could... Read the full narrative on 10x Genomics (it's free!)10x Genomics' narrative projects $688.4 million revenue and $97.8 million earnings by 2028.Uncover how 10x Genomics' forecasts yield a $17.36 fair value, a 15% downside to its current price.Exploring Other PerspectivesTXG 1-Year Stock Price Chart Six fair value estimates from the Simply Wall St Community span a wide range, from US$6.47 to US$23.59 per share, underscoring how far opinions can differ. Against that backdrop, the ImmuneScape and ASTRA collaborations highlight how future platform utilization could matter for revenue resilience, so it is worth comparing several of these viewpoints before deciding what long term performance might look like.Explore 6 other fair value estimates on 10x Genomics - why the stock might be worth as much as 15% more than the current price!Build Your Own 10x Genomics NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your 10x Genomics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.No Opportunity In 10x Genomics?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.Rare earth metals are the new gold rush. Find out which 39 stocks are leading the charge.We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602581210","isCrawlerRequest":true}